An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Monotherapy with a selective serotonin reuptake inhibitor (SSRI) is the most common initial treatment for major depressive disorder (MDD), but this monotherapy leads to remission in fewer than a third of patients. The combination of the SSRI escitalopram and bupropion-SR is commonly used for treating patients with MDD who have had an inadequate response to antidepressant monotherapy. This pilot study was conducted to evaluate this combination in the treatment of MDD in patients with chronic or recurrent MDD to estimate safety, tolerability, and remission rates. METHOD: In this study, 51 outpatients with chronic or recurrent non-psychotic MDD were treated with a combination of escitalopram and bupropion-SR for up to 12 weeks. Participants were started on escitalopram at 10 mg/day, and bupropion-SR was then added at week 1, starting at 150 mg/day. The maximum dose of escitalopram was 20 mg/day and the maximum dose of bupropion-SR was 400 mg/day. RESULTS: Rates of response (62%) and remission (50%) at study exit (based on participants for whom at least one post-baseline measure was collected) were significantly higher than is typical for SSRI monotherapy. The level of treatment emergent adverse events was low, and only 3 participants (6%) discontinued treatment due to side effects. The mean maximum dose of escitalopram was 18 mg/day, which was achieved by week 6, and the mean dose at study exit was also 18 mg/day. The mean maximum dose of bupropion-SR was 329 mg/day, which was achieved by week 8, and the mean dose at study exit was 327 mg/day. CONCLUSIONS: These results suggest that the combination of escitalopram and bupropion-SR is effective and well tolerated. Further controlled trials comparing this combination with monotherapy are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unützer, J., Katon, W., Callahan, C. M., Williams, Jr., Hunkeler, E., Harpole, L., Hoffing, M., Della Penna, R. D., Noël, P. H., Lin, E. H. B., et al. (2002) · JAMA · doi:10.1001/jama.288.22.2836 · Cited by 2,405
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“Trouble sleeping 45 33 (73) 8 (18) 1 (2) 33 1 (3) 8 (24) 24 (73) Nightmares 45 15 (33) 12 (27) 3 (7) 15 0 (0) 3 (20) 12 (80) Feeling drowsy or sleepy 45 23 (51) 15 (33) 3 (7) 23 1 (4) 3 (13) 19 (83) Feeling nervous or hyper 45 19 (42) 10 (22) 2 (4) 19 0 (0) 3 (16) 16 (84) Weakness or fatigue 45 26 (58) 10 (22) 2 (4) 2…”
Self-citationTRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
Self-citationPrevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542 · cited 2×
“7785 10% diastolic increase 9 (21) 5 (22) 4 (19) 0.”
Bodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0401 · Cited by 159
Geriatric Depression Treatment in Nonresponders to Selective Serotonin Reuptake Inhibitors
Whyte, E. M., Basinski, J., Farhi, P., Dew, M. A., Begley, A., Mulsant, B. H., & Reynolds, C. F. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1208 · Cited by 86
Cited by
Rush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., Warden, D., Morris, D. W., Luther, J. F., Husain, M. M., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111645 · Cited by 372
Self-citationCarvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Friedman, E. S., Davis, L. L., Zisook, S., Wisniewski, S. R., Trivedi, M. H., Fava, M., & Rush, A. J. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.010 · Cited by 81
“Dosing schedules were based on prior reports (Fava, 2001; Papakostas et al., 2005; McGrath et al., 2006; Leuchter et al., 2008).”
MethodSelf-citationEscitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Chan, H. N., Rush, A. J., Nierenberg, A. A., Trivedi, M., Wisniewski, S. R., Balasubramani, G. K., Friedman, E. S., Gaynes, B. N., Davis, L., Morris, D., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001660 · Cited by 30
Self-citation
Metadata
- Authors
- LEUCHTER, A. F., LESSER, I. M., TRIVEDI, M. H., RUSH, A. J., MORRIS, D. W., WARDEN, D., FAVA, M., WISNIEWSKI, S. R., LUTHER, J. F., PERALES, M., GAYNES, B. N., & STEWART, J. W.
- Venue
- Journal of Psychiatric Practice
- Published
- 2008-09
- Volume
- 14
- Issue
- 5
- Pages
- 271-280
- ISSN
- 1527-4160 (ISSN-L)
- 1538-1145
- OpenAlex
- W2049340604
- Cited by
- 45
- References
- 6
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder. https://app.cochat.ai/papers/10.1097/01.pra.0000336754.19566.65
- The paper
- LEUCHTER, A. F., LESSER, I. M., TRIVEDI, M. H., RUSH, A. J., MORRIS, D. W., WARDEN, D., FAVA, M., WISNIEWSKI, S. R., LUTHER, J. F., PERALES, M., GAYNES, B. N., & STEWART, J. W. (2008). An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder. Journal of Psychiatric Practice. https://doi.org/10.1097/01.pra.0000336754.19566.65
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.